
MI-538
CAS No. 1857417-10-7
MI-538( MI538 | MI 538 )
Catalog No. M12867 CAS No. 1857417-10-7
MI-538 is potent and selective menin–MLL interaction inhibitor (IC50=21 nM).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 213 | Get Quote |
![]() ![]() |
10MG | 375 | Get Quote |
![]() ![]() |
25MG | 627 | Get Quote |
![]() ![]() |
50MG | 893 | Get Quote |
![]() ![]() |
100MG | 1197 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMI-538
-
NoteResearch use only, not for human use.
-
Brief DescriptionMI-538 is potent and selective menin–MLL interaction inhibitor (IC50=21 nM).
-
DescriptionMI-538 is potent and selective menin–MLL interaction inhibitor (IC50=21 nM); shows the most potent binding affinity to menin (Kd = 6.5 nM) obtained for small molecule menin–MLL inhibitor reported to date; exhibits significantly increased activity, selectivity, polarity and pharmacokinetic profile over MI-136 and demonstrates a pronounced effect in a mouse model of MLL leukemia.
-
In VitroMI-538 inhibits the proliferation of MLL leukemia cells with a GI50 of 83 nM. MI-538 shows no effect (up to 6 μM) on growth of the control cell lines HL-60 and HM-2, which do not harbor MLL translocations, demonstrating good selectivity toward MLL fusion protein transformed cells. MI-538 binds to menin with low nanomolar affinity (Kd=6.5 nM). Its potent cellular activity originates from the improved binding affinity to menin and possibly increased cell membrane permeability. Treatment with MI-538 results in strong down regulation of expression of Hoxa9 and Meis1 genes. About 100 nM 27 was sufficient to reduce by ~50% Hoxa9 expression in MLL-AF9 cells, and even more pronounced effect was seen on Meis1 expression.
-
In VivoTreatment with MI-538 results in a pronounced, about 80%, reduction in the MV4;11 tumor volume, without causing substantial signs of toxicity reflected by less than 10% reduction of the body weight. MI-538 demonstrates markedly improved exposure (area under the curve, AUC, values), Cmax (maximum compound concentration) in the blood plasma, and the lowest value of clearance. The half-life of MI-538 is about 1.6 h. MI-538 has also high oral bioavailability (~50%).
-
SynonymsMI538 | MI 538
-
PathwayChromatin/Epigenetic
-
TargetHMTase
-
RecptorHMTase
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1857417-10-7
-
Formula Weight566.6006
-
Molecular FormulaC27H25F3N8OS
-
Purity>98% (HPLC)
-
SolubilityDMSO; Need ultrasonic and warming
-
SMILESN#CC(N1CC2=CNN=C2)=CC3=C1C=C(O)C(CN4CCC(NC5=C(C=C(CC(F)(F)F)S6)C6=NC=N5)CC4)=C3
-
Chemical Name1H-Indole-2-carbonitrile, 6-hydroxy-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Borkin D, et al. J Med Chem. 2016 Feb 11;59(3):892-913.
molnova catalog



related products
-
PF-06726304
PF-06726304 is a novel potent enhancer of zeste homolog 2 (EZH2) inhibitor.
-
EPZ020411 dihydrochl...
EPZ020411 is a potent, selective PRMT6 inhibitor with IC50 of 10 nM, displays 10-fold and 20-fold selectivity over PRMT1/8.
-
UNC3866
A potent, selective PRC1 chromodomains antagonist that binds to CBX4 and CBX7 with Kd of 100 nM.